Cover Image
市場調查報告書

帕金森氏症治療藥的全球市場預測

Global Parkinsons Disease Drugs Market Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 545519
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
帕金森氏症治療藥的全球市場預測 Global Parkinsons Disease Drugs Market Outlook 2022
出版日期: 2017年08月17日 內容資訊: 英文 100 Pages
簡介

本報告提供帕金森氏症治療藥的全球市場調查,整體市場趨勢,各治療類型、地區的詳細趨勢,市場變化與預測,主要產品及開發平台概要,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業簡介等系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 帕金森氏症概要

第4章 市場動態

  • 推動因素
  • 阻礙因素
  • 機會

第5章 全球帕金森氏症治療藥市場預測

第6章 主要產品

  • Duodopa/Duopa
  • Azilect
  • Mirapex/Mirapex ER
  • Requip
  • Neupro
  • Rytary/Numient
  • Xadago
  • Nuplazid

第7章 市場區隔:各治療類型

  • 左旋多巴
  • 多巴胺拮抗劑
  • 單胺氧化酵素B抑制劑(MAO-B)
  • 兒茶酚-O-甲基轉移酵素(COMT)抑制劑
  • 其他

第8章 市場區隔:各地區

  • 北美
  • 歐洲
  • 亞太地區

第9章 市場發展趨勢

  • 幹細胞療法
  • 新產品的持續性投入

第10章 合併、收購

第11章 帕金森氏症治療藥的開發平台

第12章 企業簡介

  • Abbvie Inc.
  • Newron Pharmaceuticals SpA
  • Acadia Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline plc
  • UCB S.A.
  • Novartis AG
  • Impax Laboratories, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Hoffmann-La Roche Ltd.
  • WorldMeds, LLC
目錄

Parkinson's disease belongs to the group of conditions called motor system disorders. This disease is a result of loss of dopamine producing neurons in the brain. The four primary symptoms of Parkinson's disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson's disease, several medications are used to suppress the symptoms of the disease.

As per RNCOS report "Global Parkinson's Disease Drugs Market Outlook 2022", the global Parkinson's disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson's disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson's disease and its treatment options, research grants and funds, for the global Parkinson's disease drugs market.

Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson's disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson's disease drugs market.

The global Parkinson's disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson's disease. The benefits of the medication are witnessed soon after administration.

Apart from these types of therapies, various pharmaceutical and biotech companies are also developing stem cell therapy for the treatment of Parkinson's disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson's disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients.

Numerous companies, such as SanBio Inc and International Stem Cell Corp, are carrying out clinical trials for stem cell therapies for the treatment of Parkinson's disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson's disease drugs market in the coming years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson's disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson's disease drugs industry. The drugs pipeline of Parkinson's disease has also been mentioned in the report.

The last section of the report discusses about the prominent players in global Parkinson's disease drugs market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global Parkinson's disease drugs market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Parkinson's Disease: An Overview

4. Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Increasing Funding Support & Research Grants
    • 4.1.2 Increasing Awareness
    • 4.1.3 Rising Healthcare Expenditure
    • 4.1.4 Increasing Life Expectancy
  • 4.2 Challenges
    • 4.2.1 Patent Expiry of Blockbuster Drugs
    • 4.2.2 High Cost of Treatment
    • 4.2.3 Side Effects of Parkinson's Disease Drugs
  • 4.3 Opportunities
    • 4.3.1 Collaboratios with Academic Institutions for Developing Innovative Solutions
    • 4.3.2 Reduction in "Off" Time to Improve Patient and Economic Outcomes
    • 4.3.3 Growing Geriatric Population

5. Global Parkinson's Disease Drugs Market Outlook 2022

6. Major Products in Parkinson's Disease Market

  • 6.1 Duodopa/Duopa
  • 6.2 Azilect
  • 6.3 Mirapex/Mirapex ER
  • 6.4 Requip
  • 6.5 Neupro
  • 6.6 Rytary/Numient
  • 6.7 Xadago
  • 6.8 Nuplazid

7. Market Segmentation by Type of Therapy

  • 7.1 Levodopa Therapy
  • 7.2 Dopamine Agonist Therapy
  • 7.3 MAO-B Inhibitor Therapy
  • 7.4 COMT Inhibitor Therapy
  • 7.5 Other Therapy

8. Market Segmentation by Geography

  • 8.1 North America
  • 8.2 Europe
  • 8.3 Asia-Pacific

9. Trends & Developments

  • 9.1 Stem Cell Therapies - Revolutionizing Parkinson Treatment
  • 9.2 Incessant Launch of Novel Products

10. Mergers & Acquisitions

11. Drugs Pipeline of Parkinson's Disease

12. Company Profiles

  • 12.1 Abbvie Inc.
  • 12.2 Newron Pharmaceuticals SpA
  • 12.3 Acadia Pharmaceuticals Inc.
  • 12.4 Boehringer Ingelheim International GmbH
  • 12.5 Teva Pharmaceutical Industries Limited
  • 12.6 GlaxoSmithKline plc
  • 12.7 UCB S.A.
  • 12.8 Novartis AG
  • 12.9 Impax Laboratories, Inc.
  • 12.10 Valeant Pharmaceuticals International, Inc.
  • 12.11 Merck & Co., Inc.
  • 12.12 Mylan N.V.
  • 12.13 F. Hoffmann-La Roche Ltd.
  • 12.14 US WorldMeds, LLC

List of Figures:

  • Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050
  • Figure 5-1: Global - Parkinson's Disease Drugs Market (Billion US$), 2016 & 2022
  • Figure 6-1: Global - Sales of Duodopa/Duopa (Billion US$), 2015 & 2016
  • Figure 6-2: Global - Sales of Azilect (Billion US$), 2015 & 2016
  • Figure 6-3: Global - Sales of Mirapex/Mirapex ER (Billion US$), 2015 & 2016
  • Figure 6-4: Global - Sales of Requip (Billion US$), 2015 & 2016
  • Figure 6-5: Global - Sales of Neupro (Billion US$), 2015 & 2016
  • Figure 6-6: Global - Sales of Rytary/Numient (Billion US$), 2015 & 2016
  • Figure 7-1: Global - Parkinson's Disease Drugs Market by Type of Therapy (%), 2016
  • Figure 7-2: Global - Levodopa Therapy Market for Parkinson's Disease (Billion US$), 2016 & 2022
  • Figure 7-3: Global - Dopamine Agonist Therapy Market for Parkinson's Disease (Billion US$), 2016 & 2022
  • Figure 7-4: Global - MAO-B Inhibitor Therapy Market for Parkinson's Disease (Billion US$), 2016 & 2022
  • Figure 7-5: Global - COMT Inhibitor Therapy Market for Parkinson's Disease (Billion US$), 2016 & 2022
  • Figure 7-6: Global - Other Therapy Market for Parkinson's Disease (Billion US$), 2016 & 2022
  • Figure 8-1: Global - Parkinson's Disease Drugs Market by Geography (%), 2016
  • Figure 8-2: North America - Parkinson's Disease Drugs Market (Billion US$), 2016 & 202
  • Figure 8-3: North America - Population 60 Years or Above (Million), 2015, 2030 & 2050
  • Figure 8-4: Europe - Parkinson's Disease Drugs Market (Billion US$), 2016 & 2022
  • Figure 8-5: Asia-Pacific - Parkinson's Disease Drugs Market (Billion US$), 2016 & 2022
  • Figure 12-1: Abbvie Inc. - Breakup of Revenue by Geography (%), 2016
  • Figure 12-2: Boehringer Ingelheim International GmbH - Breakup of Sales by Business Segment (%), 2016
  • Figure 12-3: Boehringer Ingelheim International GmbH - Breakup of Sales by Geography (%), 2016
  • Figure 12-4: Teva Pharmaceutical Industries Limited - Breakup of Revenue by Business Segment (%), 2016
  • Figure 12-5: Teva Pharmaceutical Industries Limited - Breakup of Revenue by Geography (%), 2016
  • Figure 12-6: GlaxoSmithKline plc - Breakup of Group Turnover by Business Segment (%), 2016
  • Figure 12-7: GlaxoSmithKline plc - Breakup of Group Turnover by Geography (%), 2016
  • Figure 12-8: UCB S.A. - Breakup of Revenue by Geography (%), 2016
  • Figure 12-9: Novartis AG - Breakup of Sales by Business Segment (%), 2016
  • Figure 12-10: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016
  • Figure 12-11: Novartis AG - Breakup of Sales by Geography (%), 2016
  • Figure 12-12: Impax Laboratories, Inc. - Breakup of Revenue by Business Segment (%), 2016
  • Figure 12-13: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Business Segment (%), 2016
  • Figure 12-14: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Geography (%), 2016
  • Figure 12-15: Merck & Co., Inc. - Sales by Business Segments (%), 2016
  • Figure 12-16: Merck & Co., Inc. - Sales by Geography (%), 2016
  • Figure 12-17: Mylan N.V. - Breakup of Revenue by Geography (%), 2016
  • Figure 12-18: F. Hoffmann-La Roche Ltd. - Breakup of Sales by Business Segment (%), 2016

List of Tables:

  • Table 10-1: Mergers, Acquisitions & Collaborations in Parkinson's Disease Drugs Market (2015-2017)
  • Table 11-1: Global - Drugs Pipeline of Parkinson's Disease
  • Table 12-1: Abbvie Inc. - Key Financials (Billion US$), 2014-2016
  • Table 12-2: Abbvie Inc. - Marketed Parkinson's Disease Products
  • Table 12-3: Abbvie Inc. - Parkinson's Disease Products in Pipeline
  • Table 12-4: Newron Pharmaceuticals SpA - Key Financials (Million US$), 2014-2016
  • Table 12-5: Newron Pharmaceuticals SpA - Marketed Parkinson's Disease Products
  • Table 12-6: Newron Pharmaceuticals SpA - Parkinson's Disease Products in Pipeline
  • Table 12-7: Acadia Pharmaceuticals Inc. - Key Financials (Million US$), 2014-2016
  • Table 12-8: Acadia Pharmaceuticals Inc. - Marketed Parkinson's Disease Products
  • Table 12-9: Boehringer Ingelheim International GmbH - Key Financials (Billion US$), 2014-2016
  • Table 12-10: Boehringer Ingelheim International GmbH - Marketed Parkinson's Disease Products
  • Table 12-11: Teva Pharmaceutical Industries Limited - Key Financials (Billion US$), 2014-2016
  • Table 12-12: Teva Pharmaceutical Industries Limited - Marketed Parkinson's Disease Products
  • Table 12-13: GlaxoSmithKline plc - Key Financials (Billion US$), 2014-2016
  • Table 12-14: GlaxoSmithKline plc - Marketed Parkinson's Disease Products
  • Table 12-15: UCB S.A. - Key Financials (Billion US$), 2014-2016
  • Table 12-16: UCB S.A. - Marketed Parkinson's Disease Products
  • Table 12-17: UCB S.A. - Parkinson's Disease Products in Pipeline
  • Table 12-18: Novartis AG - Key Financials (Billion US$), 2014-2016
  • Table 12-19: Novartis AG - Marketed Parkinson's Disease Products
  • Table 12-20: Impax Laboratories, Inc. - Key Financials (Million US$), 2014-201
  • Table 12-21: Impax Laboratories, Inc. - Marketed Parkinson's Disease Products
  • Table 12-22: Impax Laboratories, Inc. - Parkinson's Disease Products in Pipeline
  • Table 12-23: Valeant Pharmaceuticals International, Inc. - Key Financials (Billion US$), 2014-2016
  • Table 12-24: Valeant Pharmaceuticals International, Inc. - Marketed Parkinson's Disease Products
  • Table 12-25: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
  • Table 12-26: Merck & Co., Inc. - Marketed Parkinson's Disease Products
  • Table 12-27: Mylan N.V. - Key Financials (Billion US$), 2014-2016
  • Table 12-28: Mylan N.V. - Marketed Parkinson's Disease Products
  • Table 12-29: F. Hoffmann-La Roche Ltd. - Key Financials (Billion US$), 2014-2016
  • Table 12-30: F. Hoffmann-La Roche Ltd. - Marketed Parkinson's Disease Products
  • Table 12-31: F. Hoffmann-La Roche Ltd. - Parkinson's Disease Products in Pipeline
  • Table 12-32: US WorldMeds, LLC - Marketed Parkinson's Disease Products
  • Table 12-33: US WorldMeds, LLC - Parkinson's Disease Products in Pipeline
Back to Top